How much revenue does Mankind Pharma make?

Mankind Pharma reported 122.07 billion INR in revenue for fiscal year 2025, up 18.1% from 103.35 billion INR in fiscal year 2024. In Q1 2026 revenue was 35.70 billion INR.

Where does Mankind Pharma make most of its revenue?

India: 87% of revenue by region in fiscal year 2025, followed by Outside India (13%).

What companies are similar to Mankind Pharma?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Torrent Pharmaceuticals Limited (TORNTPHARM.NS), Zydus Lifesciences Limited (ZYDUSLIFE.NS), Cipla Limited (CIPLA.NS), Aurobindo Pharma Limited (AUROPHARMA.NS).

Mankind Pharma Limited (MANKIND.NS) Stock

About Mankind Pharma Limited

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, urology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respi...

At a glance

Mankind Pharma reported revenue of 122.07 billion INR for fiscal year 2025, up 18.1% from fiscal year 2024, and net income of 19.91 billion INR. In Q1 2026 (the quarter ended June 30, 2025) revenue was 35.70 billion INR, up 23.4% from a year before. India was its largest region in fiscal year 2025, with 87% of revenue.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.